|
Search
Collections
Benchmarks
Upload document
Product
FT-001
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Biallelic RPE65 Mutation-associated Retinal Dystrophy
Clinical trial
A Multi-center, Open-label, Dose-escalation Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of FT-001 Administered Via Subretinal Injection in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Status: Recruiting
, Estimated PCD: 2025-11-30